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RNA-peptide conjugates that mimic amino acid-charged tRNAs and peptidyl-tRNAs are of high impor-
tance for structural and functional investigations of ribosomal complexes. Here, we present the synthesis
of glycyl-, alanyl-, and isoleucyladenosine modiﬁed solid supports that are eligible for the synthesis of
stable 30-aminoacyl- and 30-peptidyl-tRNA termini with an amide instead of the natural ester linkage.
The present work signiﬁcantly expands the range of accessible peptidyl-tRNA mimics for ribosomal
studies.
 2011 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
X-ray and cryo-electronmicroscopy studies of the ribosome and
its subunits have revolutionized the ﬁeld of ribosome research.1–5
They bring new insights into functional and mechanistic details of
the ribosome and facilitate the design of genetic and biochemical
experiments due to the knowledge of exact residue positions. For
many structural approaches, ribosome assembly with peptidyl- or
aminoacyl-tRNA derivatives is required, however, these efforts are
often impeded because of the easily hydrolizable ester group that
connects the peptidyl and the tRNA moieties.6 A stable linkage can
overcome the limitations arising from hydrolysis, but also from ri-
bose 20-O/30-O transesteriﬁcation or transpeptidation. In analogy
to the naturally occurring antibiotic puromycin, 30-amide-linked
aminoacyl- or peptidyl-tRNAmimics fulﬁll the requirement of high-
er stability during ribosome/tRNA assembly procedures (Fig. 1).6–8
For the investigation and functional characterization of different
states of ribosomal translation, such as pre- andpost-peptidyl trans-
fer states,9–14 tRNA hybrid states,15,16 as well as translation initia-
tion,17 elongation,18,19 and termination,20,21 nonhydrolyzable tRNA
mimics are of high relevance. Furthermore, investigations of phe-
nomena such as peptide-mediated macrolide antibiotic resistance
and ribosome stalling are also dependent on this type of tRNA
derivatives.22ra).
Y-NC-ND license.For a long time, the synthesis of 30-aminoacyl- and 30-peptidyl-
RNA conjugates represented a serious bottleneck for such studies.
Although a profound fundament for their chemical synthesis was
presented by Strazewski and coworkers in 2003,23–25 signiﬁcant
improvements of the approach were required in terms of efﬁciency
which have been introduced only recently.26 The synthetic strategy
for RNA-peptide conjugates relies on 30-aminoacylamino-30-deoxy-
adenosinemodiﬁed solid supports. Thereby, the solid supportmate-
rial is attached to the 20-hydroxyl group of the adenosine moiety
(representing A76 of the tRNA30-terminus); the corresponding ami-
no acid (representing the C-terminus of the peptide chain) is linked
to the ribose 30-amino-30-deoxy modiﬁcation via an amide bond.
Here, we present the synthesis of glycyl-, alanyl-, and isoleucyl-
adenosine modiﬁed solid supports providing the above mentioned
constitutional properties and following the lines of our previously
published synthetic route.26 These supports were applied in pep-
tide and oligonucleotide synthesis and yielded the desired hydro-
lysis-resistant peptidyl-tRNA mimics after deprotection and
puriﬁcation in good yields and high purity. The present work
therefore expands the range of accessible peptidyl-tRNA mimics
which have been limited so far to methionine, phenylalanine,
and valine at the carboxy terminus of the peptide chain.26
2. Results and discussion
The starting point for our undertaking was the 30-azido-30-de-
oxyadenosine derivative 1, which was readily available from
Figure 1. Constitution and sequence annotation of an exemplary target RNA-peptide conjugate that mimics 3’-peptidyl-tRNA and comprises a hydrolysis-resistant 3’-ribose
amide linkage.
5168 J. Steger, R. Micura / Bioorg. Med. Chem. 19 (2011) 5167–51749-(b-D-arabinofuranosyl)adenine in six steps according to our
previously introduced synthesis.26 Subsequent coupling27 with
alanine, glycine or isoleucine furnished the amino acid linkedScheme 1. Synthesis of the modiﬁed solid supports 8, 9, and 10. Reaction condition
tetrahydrofuran, 0 C to rt, 16 h, 74–81%; (b) 5 equiv adipic acid bis(pentaﬂuorophenyl)es
3 equiv (w/w) amino-functionalized polystyrene support (GE Healthcare, Custom Primer S
45–63 lmol/g. Me3P = trimethylphosphine, DMAP = 4-(N,N-dimethylamino)pyridine, HObuilding blocks 2–4, which were further transformed into the
pentaﬂuorophenyl active esters 5–7 using adipic acid bis(penta-
ﬂuorophenyl)ester as linker molecule.8 Coupling of compoundss: (a) 1.3 equiv Fmoc-Ala-OBt, Fmoc-Gly-OBt or Fmoc-Ile-OBt, 2.2 equiv Me3P in
ter, 1 equiv DMAP in N,N-dimethylformamide/pyridine (1/1, v/v), rt, 1 h, 66–79%; (c)
upport™ 200 Amino), 2 equiv pyridine in N,N-dimethylformamide, rt, 22 h, loading:
Bt = N-hydroxybenzotriazole, Fmoc = N-(9-ﬂuorenyl)methoxycarbonyl.
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Primer Support™ 200 Amino) ﬁnally yielded the desired 30-
aminoacylamino-30-deoxyadenosine-functionalized solid supports
8–10 (Scheme 1).
These supports were then utilized for the elongation of the
peptide chain by automated solid-phase peptide synthesis based
on N-(9-ﬂuorenyl)methoxycarbonyl (Fmoc) protected amino acids.
Peptide synthesis was carried out using a multiple peptide synthe-
sizer (Intavis) equipped with a shaking device under standard con-
ditions. Alternatively, for the synthesis of tRNA mimics with a sole
glycine, alanine, or isoleucine unit at the 30-terminus, the solid sup-
ports 8–10 were directly supplied to RNA synthesis.
Oligoribonucleotide assembly based on 20-O-[(triisopropylsi-
lyl)oxy]methyl (20-O-TOM)28,29 protected nucleoside phosphorami-
dites was conducted on a DNA/RNA synthesizer in automated
manner following standard synthesis protocols. Furthermore, we
point out that the introduction of 50-phosphate groups at the 50-
end of RNA-peptide conjugates was accomplished as ﬁnal cycle of
the automated solid-phase synthesis by using amodiﬁed phosphor-
amidite building block prepared according to the literature.30
Deprotection under basic conditions using methylamine in
ethanol/water cleaved the cyanoethyl, acyl, amidine, and Fmoc
protecting groups and resulted in the release of the conjug-
ates from the solid support. Subsequent treatment with 1.0 MTable 1
Selection of synthesized RNA-peptide conjugates
No Sequencea
S1 5’-p-GCACCA-3’-NH-Gly-NH2
S2 5’-p-UCCCGUCAUCACCC-ACCA-3’-NH-GVFLVMox-NH2
S3 5’-p-UCCCGUCAUCACCC-ACCA-3’-NH-GVFLVM-NH2
S4 5’-p-ACCA-3’-NH-Ala-NH2
S5 5’-p-GCACCA-3’-NH-Ala-NH2
S6 5’-p-CUCCCGCCAGCUCC-ACCA-3’-NH-Ala-NH2
S7 5’-p-ACCA-3’-NH-Ile-NH2
a To indicate the correct connectivity via an amide bond, peptide sequences of the conj
code is used for RNA-peptide conjugates; amino acid three-letter code for single amino
Figure 2. Synthesis of RNA-peptide conjugates based on the modiﬁed solid
supports 9 and 10. Anion-exchange HPLC proﬁles of crude and puriﬁed (insets)
conjugates S7, S4, and S6 (A–C, upper panels) and LC-ESI mass spectra of puriﬁed
products (A–C, lower panels). Anion-exchange chromatography conditions: Dionex
DNAPac

PA-100 (4  250 mm) column; temperature: 60 C; ﬂow rate: 1 mL/min;
eluant A: 25 mM Tris–HCl (pH 8.0), 6 M urea; eluant B: 25 mM Tris–HCl (pH 8.0),
6 M urea, 500 mM NaClO4; gradient: 0–35% B in A within 30 min; UV detection at
260 nm.tetrabutylammonium ﬂuoride trihydrate (TBAF3H2O) in tetrahy-
drofuran at 37 C cleaved the 20-O-TOM groups overnight. For short
conjugates comprising only four nucleotides, 10% water was added
to the ﬂuoride deprotection solution (0.9 M TBAF3H2O in tetrahy-
drofuran/water (9/1, v/v)) and the deprotection was carried out at
room temperature. This procedure resulted in high quality crude
products which were analyzed by anion-exchange HPLC. The major
peak of the HPLC proﬁles typically represented the desired conju-
gate which was puriﬁed on a semi-preparative column to achieve
purities of more than 95%. Finally, the constitution of the products
was analyzed by LC-ESI mass spectrometry and conﬁrmed the ex-
pected molecular weights (Fig. 2).
Following this approach, we prepared the RNA-peptide conju-
gates listed in Table 1. All three supports (8–10) were ﬁrst tested
in the construction of short conjugates (S1, S4, S5, and S7) contain-
ing the highly conserved ACCA tRNA 30-terminus. The larger conju-
gate S3 represents a peptidyl-RNA fragment whose peptide portion
relates to a macrolide antibiotic resistance peptide31,32 and whose
RNA portion allows for the ligation to full-length tRNA according to
a recently introduced concept for the 30-peptidyl-tRNA semisyn-
thesis.7,8 Likewise, conjugate S6 represents a peptidyl-RNA frag-
ment appropriate for the construction of hydrolysis-resistant
tmRNA derivatives.33,34 Conjugate S2 consists of the same RNA
and peptide sequences as encountered in S3, however, the thioe-
ther moiety of methionine became oxidized during oligonucleotide
synthesis because of repeated oxidation after each coupling step
which is required for the P(III) to P(V) transformation. In the pres-
ent case, about 50% of the conjugate became oxidized and S2 and
S3 were separated during anion-exchange chromatographic puriﬁ-
cation. Alternatively, reduction of the sulfoxide moitey using N-
methylmercapto-acetamide is conceivable in analogy to reports
in the literature.35 To handle oxidation of the methionine moiety,
one may also consider replacement of the aqueous iodine solution
used here by tert-butyl hydroperoxide solution in THF or acetoni-
trile during oligonucleotide solid-phase synthesis.36 This alterna-
tive oxidizing reagent has been used for example, for synthesis of
spin-labeled, nitroxide containing oligonucleotides,37 but also for
RNA containing other oxidation-sensitive moieties, such as 2-thio-
uridines38 or 20-methylseleno groups.39 Preliminary experiments
using tert-butyl hydroperoxide solutions for the synthesis of the
RNA-peptide conjugates presented here,40 however, were unsuc-
cessful in our hands.
A critical view on the synthetic approach presented reveals that
there are some limitations concerning the variability of the peptide
sequence. In short, amino acid side chains that can be protected by
silyl- or allyl-protecting groups during conjugate synthesis are
compatible, and RNA-peptide conjugates containing serine,
threonine, tyrosine, as well as glutamic or aspartic acid are acces-
sible.25,26 Furthermore, preliminary experiments on the incorpora-
tion of cysteine with disulﬁde protection were promising. More
difﬁculties were encountered for arginine containing conjugates
for which we are currently exploring alternatives based on native
chemical ligation.41Amount [nmol] M.W.calcd [amu] M.W.found [amu]
185 1993.2 1993.0
32 6312.2 6312.5
35 6296.2 6296.5
118 1356.9 1356.7
123 2007.3 2007.1
186 5735.5 5735.3
112 1399.0 1398.9
ugates are written unconventionally (from C- to N-terminus). Amino acid one-letter
acid-RNA conjugates.
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The functionalized solid supports (8–10) whose efﬁcient syn-
thesis is presented in this work increase amino acid side chain ﬂex-
ibility of hydrolysis-resistant 30-peptidyl-tRNA mimics and
therefore expand the scope of applications of these derivatives
which are required to explore mechanistic details of ribosomal
translation.22 Our approach is characterized by easy handling, high
efﬁciency and high reliability. The given examples of synthetic con-
jugates represent tRNA fragments that are also suited for enzy-
matic ligation to the corresponding full-length tRNA derivatives.7
They are considered to further consolidate and disseminate our re-
cently introduced semisynthetic strategy for chemically modiﬁed
tRNA species that relies on site-speciﬁc cleavage of natural tRNAs
by DNA enzymes followed by enzymatic ligation using synthetic
fragments as prepared in this study.7,84. Experimental
4.1. Solid support synthesis
4.1.1. General remarks
1H and 13C NMR spectra were recorded on a Bruker UltraShield™
Plus 600 MHz instrument. The chemical shifts (d) are reported rel-
ative to tetramethylsilane (TMS) and referenced to the residual pro-
ton signal of the deuterated solvent CDCl3: 7.26 ppm for 1H NMR
spectra or 77.1 ppm for 13C NMR spectra. 1H and 13C assignments
are based on COSY and HSQC experiments. MS experiments were
performed on a Finnigan LCQ Advantage MAX ion trap instrumen-
tation (Thermo Fisher Scientiﬁc) with an electrospray ion source.
Samples were analyzed in the positive- or negative-ionmode. Reac-
tion control was performed via analytical thin-layer chromatogra-
phy (TLC, Macherey–Nagel) with ﬂuorescent indicator. Column
chromatography was carried out on Silica gel 60 (70–230 mesh).
Chemical reagents and solvents were purchased from commercial
suppliers (Sigma–Aldrich, Acros, IRIS Biotech GmbH) and used with-
out further puriﬁcation. Custom Primer Support™ 200 Amino was
purchased from GE Healthcare. Organic solvents for reactions were
dried overnight over freshly activated molecular sieves (4 Å). The
reactions were carried out under argon atmosphere.
4.1.2. 6-N-[(Di-n-butylamino)methylene]-30-{[N-(9-ﬂuorenyl)
methoxycarbonyl-L-glycyl]amino}-30-deoxy-50-O-(4,40-dime-
thoxytrityl)-b-D-adenosine (2)
N-(9-Fluorenyl)methoxycarbonyl-L-glycine (132 mg, 0.443
mmol) was co-evaporated three times with dry tetrahydrofuran
and then dissolved in 6.5 mL dry tetrahydrofuran. After cooling the
solution to 0 C, 1-hydroxybenzotriazole hydrate (78 mg, 0.509
mmol) was added. The solution was stirred for 10 min and N,N-
diisopropylcarbodiimide (90 lL, 0.581 mmol) was added. After 10
more minutes, compound 1 (250 mg, 0.341 mmol), which was dis-
solved in 9.8 mL dry tetrahydrofuran, was slowly dropped into the
solution. Then, 15 min later trimethylphosphine in tetrahydrofuran
(715 lL, 0.715 mmol, 1.0 M in tetrahydrofuran) was added. The
solution was allowed to warm to room temperature and stirred for
16 h. The solvent and the volatile compounds were evaporated un-
der reduced pressure and the residue was dissolved in dichloro-
methane. The solution was extracted with water and with half
saturated sodium bicarbonate solution. The organic layers were
dried over Na2SO4 and evaporated. Compound2was puriﬁed by col-
umn chromatography on SiO2 with dichloromethane/methanol,
99.5:0.5–97:3. Yield: 249 mg of 2 as white foam (74%). TLC (8%
methanol indichloromethane):Rf = 0.42. 1HNMR(600 MHz,CDCl3):
d 0.97 (q, J = 7.3 Hz, 6H, N(CH2CH2CH2CH3)2); 1.39 (td, J1 = 7.7 Hz,
J2 = 15.6 Hz, 4H, N(CH2CH2CH2CH3)2); 1.67 (tt, J1 = 7.3 Hz,J2 = 14.7 Hz, 4H, N(CH2CH2CH2CH3)2); 3.40–3.52 (m, 4H,
N(CH2CH2CH2CH3), H(a)-C(50), H(b)-C(50)); 3.67–3.76 (m, 8H,
N(CH2CH2CH2CH3)), 2 O–CH3(DMT)); 3.79–3.94 (m, 2H, H2C(a,
Gly)); 4.22 (t, J = 6.8 Hz, 1H, H–C(9, Fmoc)); 4.41–4.43 (m, 3H, H–
C(40), O–CH2(Fmoc)); 4.60 (m, 1H, H–C(30)); 4.88 (s, 1H, H–C(20));
5.58 (s, br, 1H, HN(Gly)); 5.96 (s, 1H, H–C(10)); 6.31 (s, br, 1H, HO–
C(20)); 6.77 (d, J = 7.7 Hz, 4H, H–C(ar)); 6.92 (m, 1H, HN–C(30));
7.15–7.31 (m, 13H, H–C(ar)); 7.35–7.40 (m, 2H, H–C(ar)); 7.59 (d,
J = 6.6 Hz, 2H, H–C(ar)); 7.75 (d, J = 7.6 Hz, 2H, H–C(ar)); 8.14 (s,
1H, H–C(8)); 8.47 (s, 1H, H–C(2)); 9.07 (s, 1H, HC@N–C(6)) ppm.
13C NMR (150 MHz, CDCl3): d 13.75, 13.99 (N(CH2CH2CH2CH3)2);
19.85, 20.29 (N(CH2CH2CH2CH3)2); 29.35, 31.05 (N(CH2CH2CH2
CH3)2); 44.58 (C(a, Gly)); 45.36 (N(CH2CH2CH2CH3)); 47.16 (C(9,
Fmoc)); 52.06 (N(CH2CH2CH2CH3)); 52.78 (C(30)); 55.25 (2 O–
CH3(DMT)); 63.65 (C(50)); 67.36 (O–CH2(Fmoc)); 74.59 (C(20));
80.07; 84.38 (C(40)); 86.67; 91.36 (C(10)); 113.22, 120.06, 125.10,
126.39, 126.90, 127.16, 127.81, 127.89, 128.21, 130.13 (C(ar));
135.69; 135.73; 139.54 (C(8)); 141.36; 143.80; 144.54; 150.66;
152.29 (C(2)); 156.65; 158.56; 158.93; 160.50; 169.53 ppm. ESI-
MS (m/z): [M+H]+ calcd for C57H62N8O8, 988.15. Found 987.42.
4.1.3. 6-N-[(Di-n-butylamino)methylene]-30-{[N-(9-ﬂuorenyl)
methoxycarbonyl-L-alanyl]amino}-30-deoxy-50-O-(4,40-dime-
thoxytrityl)-b-D-adenosine (3)
N-(9-Fluorenyl)methoxycarbonyl-L-alanine (138 mg, 0.443
mmol) was co-evaporated three times with dry tetrahydrofuran
and then dissolved in 6.5 mL dry tetrahydrofuran. After cooling the
solution to 0 C, 1-hydroxybenzotriazole hydrate (78 mg,
0.509 mmol) was added. The solution was stirred for 10 min and
N,N-diisopropylcarbodiimide (90 lL, 0.581 mmol) was added. After
10 more minutes, compound 1 (250 mg, 0.341 mmol), which was
dissolved in 9.8 mL dry tetrahydrofuran, was slowly dropped into
the solution. Then, 15 min later trimethylphosphine in tetrahydro-
furan (715 lL, 0.715 mmol, 1.0 M in tetrahydrofuran) was added.
The solution was allowed to warm to room temperature and stirred
for 16 h. The solvent and the volatile compounds were evaporated
under reduced pressure and the residue was dissolved in dichloro-
methane. The solutionwas extractedwithwater andwith half satu-
rated sodium bicarbonate solution. The organic layers were dried
over Na2SO4 and evaporated. Compound 3 was puriﬁed by column
chromatography on SiO2 with dichloromethane/methanol, 99:1–
97:3. Yield: 275 mg of 3 as white foam (81%). TLC (8% methanol in
dichloromethane): Rf = 0.48. 1H NMR (600 MHz, CDCl3): d 0.97 (q,
J = 7.0 Hz, 6H,N(CH2CH2CH2CH3)2); 1.36–1.44 (m, 7H,N(CH2CH2CH2
CH3)2, H3C(b, Ala)); 1.68 (tt, J1 = 7.7 Hz, J2 = 15.4 Hz, 4H,
N(CH2CH2CH2CH3)2); 3.40–3.44 (m, 3H, N(CH2CH2CH2CH3), H(a)-
C(50)); 3.49 (dd, J1 = 2.6 Hz, J2 = 10.6 Hz, 1H, H(b)-C(50)); 3.69–3.78
(m, 8H, N(CH2CH2CH2CH3)), 2 O–CH3(DMT)); 4.21–4.24 (m, 2H,
H–C(a, Ala), H–C(9, Fmoc)); 4.38–4.43 (m, 3H, H–C(40), O–
CH2(Fmoc)); 4.60 (m, 1H, H–C(30)); 4.86 (t, J = 4.9 Hz, 1H, H–C(20));
5.35 (d, J = 6.4 Hz, 1H, HN(Ala)); 5.97 (s, 2H, H–C(10), HO–C(20));
6.77 (dd, J1 = 2.2 Hz, J2 = 8.7 Hz, 4H, H–C(ar)); 6.82 (d, J = 4.8 Hz,
1H, HN–C(30)); 7.18–7.41 (m, 13H, H–C(ar)); 7.58 (t, J = 8.2 Hz, 2H,
H–C(ar)); 7.76 (t, J = 6.6 Hz, 2H, H–C(ar)); 8.15 (s, 1H, H–C(8)); 8.50
(s, 1H, H–C(2)); 9.07 (s, 1H, HC@N–C(6)) ppm. 13C NMR (150 MHz,
CDCl3): d 13.76, 13.99 (N(CH2CH2CH2CH3)2); 18.67 (C(b, Ala));
19.85, 20.29 (N(CH2CH2CH2CH3)2); 29.35, 31.06 (N(CH2CH2CH2
CH3)2); 45.33 (N(CH2CH2CH2CH3)); 47.15 (C(9, Fmoc)); 50.69 (C(a,
Ala)); 52.02 (N(CH2CH2CH2CH3)); 52.51 (C(30)); 55.25 (2 O–
CH3(DMT)); 63.36 (C(50)); 67.26 (O–CH2(Fmoc)); 74.64 (C(20));
80.07; 83.60 (C(40)); 86.60; 91.33 (C(10)); 113.22, 120.04, 120.07,
125.06, 125.11, 126.43, 126.89, 127.14, 127.16, 127.81, 127.91,
128.22, 130.13 (C(ar)); 135.67; 135.70; 139.54 (C(8)); 141.33;
141.36; 143.70; 143.83; 144.51; 150.63; 152.39 (C(2)); 156.16;
158.56; 158.87; 160.48; 173.01 ppm. ESI-MS (m/z): [M+H]+ calcd
for C58H64N8O8, 1002.18. Found 1001.67.
J. Steger, R. Micura / Bioorg. Med. Chem. 19 (2011) 5167–5174 51714.1.4. 6-N-[(Di-n-butylamino)methylene]-30-{[N-(9-ﬂuorenyl)
methoxycarbonyl-L-isoleucyl]amino}-30-deoxy-50-O-(4,40-di
methoxytrityl)-b-D-adenosine (4)
N-(9-Fluorenyl)methoxycarbonyl-L-isoleucine (179 mg,
0.506 mmol) was three times co-evaporated with dry tetrahydro-
furan and then dissolved in 8.2 mL dry tetrahydrofuran. After cool-
ing the solution to 0 C, 1-hydroxybenzotriazole hydrate (103 mg,
0.673 mmol) was added. The solution was stirred for 10 min and
N,N-diisopropylcarbodiimide (104 lL, 0.673 mmol) was added.
After 10 more minutes compound 1 (286 mg, 0.389 mmol), which
was dissolved in 11.1 mL dry tetrahydrofuran, was slowly dropped
into the solution. Then, 15 min later trimethylphosphine in tetra-
hydrofuran (848 lL, 0.848 mmol, 1.0 M in tetrahydrofuran) was
added. The solution was allowed to warm to room temperature
and stirred for 16 h. The solvent and the volatile compounds were
evaporated under reduced pressure and the residue was dissolved
in dichloromethane. The solution was extracted with water and
with half saturated sodium bicarbonate solution. The organic lay-
ers were dried over Na2SO4 and evaporated. Compound 4was puri-
ﬁed by column chromatography on SiO2 with dichloromethane/
methanol, 99.5:0.5–97:3. Yield: 304 mg of 4 as white foam (75%).
TLC (8% methanol in dichloromethane): Rf = 0.50. 1H NMR
(600 MHz, CDCl3): d 0.78 (d, J = 6.7 Hz, 3H, H3C(c0, Ile)); 0.87 (t,
J = 7.2 Hz, 3H, H3C(d, Ile)); 0.97 (q, J = 6.5 Hz, 6H, N(CH2CH2CH2
CH3)2); 1.07–1.12 (m, 1H, H(a)-C(c, Ile)); 1.36–1.44 (m, 4H,
N(CH2CH2CH2CH3)2); 1.49 (m, 1H, H(b)-C(c, Ile)); 1.67–1.72 (m,
4H, N(CH2CH2CH2CH3)2); 1.75–1.76 (m, 1H, H–C(b, Ile)); 3.33–
3.36 (m, 1H, H(a)-C(50)); 3.41–3.46 (m, 3H, N(CH2CH2CH2CH3),
H(b)-C(50)); 3.69 (dt, 1H, J1 = 7.1 Hz, J2 = 13.7 Hz, N(H(a)CH(b)CH2
CH2CH3)); 3.75–3.80 (m, 7H, N(H(a)CH(b)CH2CH2CH3), 2 O–
CH3(DMT)); 4.04 (t, J = 8.0 Hz, 1H, H–C(a, Ile)); 4.18 (t, J = 6.7 Hz,
1H, H–C(9, Fmoc)); 4.33–4.34 (m, 3H, H–C(40), O–CH2(Fmoc));
4.69–4.72 (m, 1H, H–C(30)); 4.77 (m, 1H, H–C(20)); 5.47 (d,
J = 8.9 Hz, 1H, HN(Ile)); 6.05 (s, 1H, H–C(10)); 6.14 (s, 1H, HO–
C(20)); 6.78 (d, J = 7.8 Hz, 4H, H–C(ar)); 6.84 (d, J = 5.6 Hz, 1H,
HN–C(30)); 7.18–7.33 (m, 10H, H–C(ar)); 7.38 (t, J = 7.1 Hz, 3H,
H–C(ar)); 7.55 (dd, J1 = 7.7 Hz, J2 = 16.8 Hz, 2H, H–C(ar)); 7.73
(dd, J1 = 7.6 Hz, J2 = 15.6 Hz, 2H, H–C(ar)); 8.18 (s, 1H, H–C(8));
8.54 (s, 1H, H–C(2)); 9.07 (s, 1H, HC@N–C(6)) ppm. 13C NMR
(150 MHz, CDCl3): d 11.34 (C(d, Ile)); 13.74, 13.98 (N(CH2CH2CH2
CH3)2); 15.37 (C(c0, Ile)); 19.83, 20.27 (N(CH2CH2CH2CH3)2); 25.07
(C(c, Ile)); 29.34, 31.05 (N(CH2CH2CH2CH3)2); 37.51 (C(b, Ile));
45.31 (N(CH2CH2CH2CH3)); 47.17 (C(9, Fmoc)); 51.93 (C(30));
52.00 (N(CH2CH2CH2CH3)); 55.22 (2 O–CH3(DMT)); 59.66 (C(a,
Ile)); 63.11 (C(50)); 67.16 (O–CH2(Fmoc)); 74.64 (C(20)); 80.06;
83.12 (C(40)); 86.53; 91.42 (C(10)); 113.20, 119.99, 120.05, 125.07,
126.43, 126.87, 127.10, 127.16, 127.77, 127.79, 127.89, 128.26,
130.16 (C(ar)); 135.64; 139.51 (C(8)); 141.27; 141.34; 143.66;
143.82; 144.45; 150.58; 152.47 (C(2)); 156.47; 158.55; 158.89;
160.45; 171.92 ppm. ESI-MS (m/z): [M+H]+ calcd for C61H70N8O8,
1044.26. Found 1043.55.
4.1.5. 6-N-[(Di-n-butylamino)methylene]-30-{[N-(9-ﬂuorenyl)
methoxycarbonyl-L-glycyl]amino}-30-deoxy-50-O-(4,40-dimeth-
oxytrityl)-20-O-[1,6-dioxo-6-(pentaﬂuorophenyloxy) hexyl]-b-D-
adenosine (5)
Compound 2 (221 mg, 0.224 mmol) was dissolved in 2.9 mL dry
N,N-dimethylformamide and 2.9 mL dry pyridine. After addition of
4-(N,N-dimethylamino)pyridine (27 mg, 0.221 mmol) and adipic
acid bis(pentaﬂuorophenyl)ester (524 mg, 1.10 mmol) the solution
was stirred for 2 h at room temperature. The reaction mixture was
evaporated under reduced pressure and afterwards the residue
was co-evaporated three times with toluene and once with dichlo-
romethane. Compound 5 was puriﬁed by column chromatography
on SiO2 with dichloromethane/acetone, 95:5–80:20. Yield: 192 mg
of 5 as white foam (67%). TLC (15% acetone in dichloromethane):Rf = 0.31. 1H NMR (600 MHz, CDCl3): d 0.97 (dt, J1 = 7.5 Hz,
J2 = 15.7 Hz, 6H, N(CH2CH2CH2CH3)2); 1.35–1.41 (m, 4H,
N(CH2CH2CH2CH3)2); 1.65–1.68 (m, 4H, N(CH2CH2CH2CH3)2); 1.73
(m, 4H, OOCCH2CH2CH2CH2COO); 2.42–2.44 (m, 2H, OOCCH2CH2
CH2CH2COO); 2.65–2.67 (m, 2H, OOCCH2CH2CH2CH2COO); 3.41 (t,
J = 7.3 Hz, 2H, N(CH2CH2CH2CH3)); 3.47–3.49 (m, 2H, H(a)-C(50),
H(b)-C(50)); 3.68–3.73 (m, 2H, N(CH2CH2CH2CH3)); 3.78 (s, 6H,
2 O–CH3(DMT)); 3.81 (t, J = 6.7 Hz, 2H, H2C(a, Gly)); 4.14 (dt,
J1 = 3.8 Hz, J2 = 7.7 Hz, 1H, H–C(40)); 4.23 (t, J = 6.7 Hz, 1H, H–C(9,
Fmoc)); 4.47 (d, J = 6.8 Hz, 2H, O–CH2(Fmoc)); 5.23 (q, J = 7.2 Hz,
1H, H–C(30)); 5.41 (s, br, 1H, HN(Gly)); 5.84 (d, J = 2.7 Hz, 1H, H–
C(20)); 6.16 (d, J = 2.8 Hz, 1H, H–C(10)); 6.40 (d, J = 6.5 Hz, 1H,
HN–C(30)); 6.80 (dd, J1 = 2.7 Hz, J2 = 8.9 Hz, 4H, H–C(ar)); 7.19 (t,
J = 7.2 Hz, 1H, H–C(ar)); 7.25–7.32 (m, 8H, H–C(ar)); 7.39–7.42
(m, 4H, H–C(ar)); 7.58 (d, J = 6.8 Hz, 2H, H–C(ar)); 7.77 (d,
J = 6.1 Hz, 2H, H–C(ar)); 8.07 (s, 1H, H–C(8)); 8.52 (s, 1H, H–
C(2)); 9.00 (s, 1H, HC@N–C(6)) ppm. 13C NMR (150 MHz, CDCl3):
d 13.76, 13.96 (N(CH2CH2CH2CH3)2); 19.86, 20.25 (N(CH2CH2CH2
CH3)2); 23.77, 23.95 (OOCCH2CH2CH2CH2COO); 29.33, 31.08
(N(CH2CH2CH2CH3)2); 32.86 (OOCCH2CH2CH2CH2COO); 33.26
(OOCCH2CH2CH2CH2COO); 44.88 (C(a, Gly)); 45.31 (N(CH2CH2CH2
CH3)); 47.15 (C(9, Fmoc)); 50.75 (C(30)); 51.97 (N(CH2CH2CH2
CH3)); 55.28 (2 O–CH3(DMT)); 63.22 (C(50)); 67.32 (O–
CH2(Fmoc)); 75.29 (C(20)); 82.26 (C(40)); 86.87; 87.57 (C(10));
100.07; 113.24, 120.14, 124.93, 126.13, 126.96, 127.19, 127.93,
128.25, 129.22, 130.21 (C(ar)); 135.58; 135.66; 137.01; 138.79;
139.91 (C(8)); 140.38; 141.39; 142.00; 143.62; 143.65; 144.47;
151.17; 153.00 (C(2)); 156.88; 158.43; 158.60; 160.17; 169.01;
169.42; 171.50 ppm. ESI-MS (m/z): [M+H]+ calcd for
C69H69F5N8O11, 1282.33. Found 1281.39.
4.1.6. 6-N-[(Di-n-butylamino)methylene]-30-{[N-(9-ﬂuorenyl)
methoxycarbonyl-L-alanyl]amino}-30-deoxy-50-O-(4,40-dimeth-
oxytrityl)-20-O-[1,6-dioxo-6-(pentaﬂuorophenyloxy) hexyl]-b-D-
adenosine (6)
Compound 3 (227 mg, 0.227 mmol) was dissolved in 2.9 mL dry
N,N-dimethylformamide and 2.9 mL dry pyridine. After addition of
4-(N,N-dimethylamino)pyridine (28 mg, 0.229 mmol) and adipic
acid bis(pentaﬂuorophenyl)ester (533 mg, 1.11 mmol) the solution
was stirred for 2 h at room temperature. The reaction mixture was
evaporated under reduced pressure and afterwards the residue
was co-evaporated three times with toluene and once with dichlo-
romethane. Compound 6 was puriﬁed by column chromatography
on SiO2 with dichloromethane/acetone, 95:5–80:20. Yield: 195 mg
of 6 as white foam (66%). TLC (15% acetone in dichloromethane):
Rf = 0.40. 1H NMR (600 MHz, CDCl3): d 0.94–0.99 (m, 6H,
N(CH2CH2CH2CH3)2); 1.28–1.29 (m, 3H, H3C(b, Ala)); 1.36–1.40
(m, 4H, N(CH2CH2CH2CH3)2); 1.65–1.68 (m, 8H, N(CH2CH2CH2
CH3)2, OOCCH2CH2CH2CH2COO); 2.42 (t, J = 4.5 Hz, 2H, OOCCH2CH2
CH2CH2COO); 2.60 (t, J = 4.6 Hz, 2H, OOCCH2CH2CH2CH2COO); 3.41
(t, J = 6.9 Hz, 2H, N(CH2CH2CH2CH3)); 3.46 (m, 2H, H(a)-C(50), H(b)-
C(50)); 3.65–3.72 (m, 2H, N(CH2CH2CH2CH3)); 3.78 (s, 6H, 2 O–
CH3(DMT)); 4.15–4.22 (m, 3H, H–C(a, Ala), H–C(40), H–C(9, Fmoc));
4.37 (m, 1H, O–H(a)CH(b)(Fmoc)); 4.45–4.48 (m, 1H, O–H(a)CH(b)
(Fmoc)); 5.28–5.25 (m, 1H, H–C(30)); 5.27 (s, br, 1H, HN(Ala));
5.84–5.85 (m, 1H, H–C(20)); 6.16 (m, 1H, H–C(10)); 6.52 (s, br, 1H,
HN–C(30)); 6.80 (d, J = 8.4 Hz, 4H, H–C(ar)); 7.19 (t, J = 6.8 Hz, 1H,
H–C(ar)); 7.25–7.32 (m, 8H, H–C(ar)); 7.39–7.42 (m, 4H, H–
C(ar)); 7.57 (d, J = 6.8 Hz, 2H, H–C(ar)); 7.76 (d, J = 6.8 Hz, 2H, H–
C(ar)); 8.08 (s, 1H, H–C(8)); 8.52 (s, 1H, H–C(2)); 8.99 (s, 1H,
HC@N–C(6)) ppm. 13C NMR (150 MHz, CDCl3): d 13.75, 13.93
(N(CH2CH2CH2CH3)2); 17.71 (C(b, Ala)); 19.86, 20.24 (N(CH2CH2
CH2CH3)2); 23.74, 23.97 (OOCCH2CH2CH2CH2COO); 29.33, 31.08
(N(CH2CH2CH2CH3)2); 32.84 (OOCCH2CH2CH2CH2COO); 33.28
(OOCCH2CH2CH2CH2COO); 45.33 (N(CH2CH2CH2CH3)); 47.15 (C(9,
Fmoc)); 50.47 (C(a, Ala)); 50.66 (C(30)); 51.98 (N(CH2CH2CH2CH3));
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75.25 (C(20)); 80.08; 82.43 (C(40)); 86.81; 87.58 (C(10)); 109.45;
113.26, 120.12, 124.95, 125.01, 126.05, 126.94, 127.18, 127.92,
128.30, 129.23, 130.18 (C(ar)); 135.58; 135.68; 137.12; 137.91;
138.75; 139.96; 140.34; 141.37; 142.02; 143.64; 143.71; 144.42;
151.15 (C(2)); 152.97; 156.28; 158.46; 158.63; 160.13; 169.44;
171.48; 172.11 ppm. ESI-MS (m/z): [M+H]+ calcd for C70H71F5N8
O11, 1296.35. Found 1295.30.
4.1.7. 6-N-[(Di-n-butylamino)methylene]-30-{[N-(9-ﬂuorenyl)
methoxycarbonyl-L-isoleucyl]amino}-30-deoxy-50-O-(4,40-dime-
thoxytrityl)-20-O-[1,6-dioxo-6-(pentaﬂuorophenyloxy) hexyl]-b-
D-adenosine (7)
Compound 4 (209 mg, 0.200 mmol) was dissolved in 2.9 mL dry
N,N-dimethylformamide and 2.9 mL dry pyridine. After addition of
4-(N,N-dimethylamino)pyridine (25 mg, 0.205 mmol) and adipic
acid bis(pentaﬂuorophenyl)ester (470 mg, 0.983 mmol) the solu-
tion was stirred for 2 h at room temperature. The reaction mixture
was evaporated under reduced pressure and afterwards the resi-
due was co-evaporated three times with toluene and once with
dichloromethane. Compound 7 was puriﬁed by column chroma-
tography on SiO2 with dichloromethane/acetone, 95:5–85:15.
Yield: 213 mg of 7 as white foam (79%). TLC (15% acetone in dichlo-
romethane): Rf = 0.58. 1H NMR (600 MHz, CDCl3): d 0.73 (d,
J = 6.7 Hz, 3H, H3C(c0, Ile)); 0.86 (t, J = 7.2 Hz, 3H, H3C(d, Ile));
0.97 (q, J = 7.3 Hz, 6H, N(CH2CH2CH2CH3)2); 1.04–1.07 (m, 1H,
H(a)-C(c, Ile)); 1.37–1.43 (m, 4H, N(CH2CH2CH2CH3)2); 1.47–1.49
(m, 1H, H(b)-C(c, Ile)); 1.63–1.71 (m, 8H, N(CH2CH2CH2CH3)2,
OOCCH2CH2CH2CH2COO); 1.79–1.80 (m, 1H, H–C(b, Ile)); 2.44–
2.46 (m, 2H, OOCCH2CH2CH2CH2COO); 2.57–2.67 (m, 2H,
OOCCH2CH2CH2CH2COO); 3.40–3.43 (m, 3H, N(CH2CH2CH2CH3),
H(a)-C(50)); 3.47 (dd, J1 = 5.1 Hz, J2 = 10.6 Hz, 1H, H(b)-C(50));
3.70–3.76 (m, 2H, N(CH2CH2CH2CH3)); 3.78 (s, 6H, 2 O–CH3
(DMT)); 3.83 (t, J = 6.9 Hz, 2H, H–C(a, Ile)); 4.19–4.23 (m, H–C(9,
Fmoc), H–C(40)); 4.33 (t, J = 8.4 Hz, 1H, O–H(a)CH(b)(Fmoc)); 4.44
(dd, J1 = 7.0 Hz, J2 = 10.5 Hz, 1H, O–H(a)CH(b)(Fmoc)); 5.26–5.27
(m, 2H, H–C(30), HN(Ile)); 5.83 (dd, J1 = 2.7 Hz, J2 = 6.0 Hz, 1H, H–
C(20)); 6.17 (d, J = 2.8 Hz, 1H, H–C(10)); 6.27 (d, J = 7.5 Hz, 1H,
HN–C(30)); 6.6.77–6.79 (m, 4H, H–C(ar)); 7.19 (t, J = 7.3 Hz, 1H,
H–C(ar)); 7.25 (t, J = 7.6 Hz, 2H, H–C(ar)); 7.28–7.31 (m, 6H, H–
C(ar)); 7.37–7.42 (m, 4H, H–C(ar)); 7.57 (t, J = 6.5 Hz, 2H, H–
C(ar)); 7.76 (dd, J1 = 3.3 Hz, J2 = 7.5 Hz, 2H, H–C(ar)); 8.05 (s, 1H,
H–C(8)); 8.52 (s, 1H, H–C(2)); 8.99 (s, 1H, HC@N–C(6)) ppm. 13C
NMR (150 MHz, CDCl3): d 10.98 (C(d, Ile)); 13.70, 13.93
(N(CH2CH2CH2CH3)2); 15.39 (C(c0, Ile)); 19.80, 20.23 (N(CH2CH2CH2
CH3)2); 23.67, 23.91 (OOCCH2CH2CH2CH2COO); 24.75 (C(c, Ile));
29.28, 31.04 (N(CH2CH2CH2CH3)2); 32.77 (OOCCH2CH2CH2CH2-
COO); 33.25 (OOCCH2CH2CH2CH2COO); 36.38 (C(b, Ile)); 45.22
(N(CH2CH2CH2CH3)); 47.11 (C(9, Fmoc)); 50.75 (C(30)); 51.87
(N(CH2CH2CH2CH3)); 55.18 (2 O–CH3(DMT)); 59.70 (C(a, Ile));
63.21 (C(50)); 67.10 (O-CH2(Fmoc)); 75.15 (C(20)); 82.34 (C(40));
86.62; 87.62 (C(10)); 100.01; 113.16, 120.02, 124.99, 126.23,
126.86, 127.11, 127.80, 127.86, 128.21, 130.10 (C(ar)); 135.44;
135.57; 137.01; 138.70; 139.83; 141.29; 141.94; 143.65; 144.33;
151.19; 153.04 (C(2)); 156.36; 158.31; 158.52; 160.18; 169.36;
171.20; 171.36 ppm. ESI-MS (m/z): [M+H]+ calcd for C72H77F5
N8O11, 1338.43. Found 1337.29.
4.1.8. DMTO-rA-30-NH-Gly-NHFmoc solid support (8)
To a solution of active ester 5 (177 mg, 0.138 mmol) in 3.0 mLdry
N,N-dimethylformamide was added amino-functionalized support
(GE Healthcare, Custom Primer Support™ 200 Amino, 530 mg) and
pyridine (22 lL, 0.271 mmol). The suspension was agitated for
22 hat roomtemperature and thebeadswere collectedonaBüchner
funnel. The beads were washed with N,N-dimethylformamide,
methanol, and dichloromethane and dried. Capping was performedby treatmentof thebeadswithamixtureof6.0 mLof solutionA (ace-
tic anhydride/2,4,6-trimethylpyridine/acetonitrile, 2/3/5) and
6.0 mL of solution B (4-(N,N-dimethylamino)pyridine/acetonitrile,
0.5 M) for 10 minat room temperature. The suspensionwasﬁltrated
again and the beads were washed with acetonitrile, methanol, and
dichloromethane and dried under vacuum. Loading of the support
10was 63 lmol/g.
4.1.9. DMTO-rA-30-NH-Ala-NHFmoc solid support (9)
To a solution of active ester 6 (175 mg, 0.135 mmol) in 3.0 mL
dry N,N-dimethylformamide was added amino-functionalized sup-
port (GE Healthcare, Custom Primer Support™ 200 Amino, 525 mg)
and pyridine (22 lL, 0.271 mmol). The suspension was agitated for
22 h at room temperature and the beads were collected on a Büch-
ner funnel. The beads were washed with N,N-dimethylformamide,
methanol, and dichloromethane and dried. Capping was performed
by treatment of the beads with a mixture of 6.0 mL of solution A
(acetic anhydride/2,4,6-trimethylpyridine/acetonitrile, 2/3/5) and
6.0 mL of solution B (4-(N,N-dimethylamino)pyridine/acetonitrile,
0.5 M) for 10 min at room temperature. The suspension was ﬁl-
trated again and the beads were washed with acetonitrile, metha-
nol, and dichloromethane and dried under vacuum. Loading of the
support 8 was 45 lmol/g.
4.1.10. DMTO-rA-30-NH-Ile-NHFmoc solid support (10)
To a solution of active ester 7 (223 mg, 0.167 mmol) in 3.5 mL
dry N,N-dimethylformamide was added amino-functionalized sup-
port (GE Healthcare, Custom Primer Support™ 200 Amino, 668 mg)
and pyridine (27 lL, 0.332 mmol). The suspension was agitated for
22 h at room temperature and the beads were collected on a Büch-
ner funnel. The beads were washed with N,N-dimethylformamide,
methanol, and dichloromethane and dried. Capping was performed
by treatment of the beads with a mixture of 6.0 mL of solution A
(acetic anhydride/2,4,6-trimethylpyridine/acetonitrile, 2/3/5) and
6.0 mL of solution B (4-(N,N-dimethylamino)pyridine/acetonitrile,
0.5 M) for 10 min at room temperature. The suspension was ﬁl-
trated again and the beads were washed with acetonitrile, metha-
nol, and dichloromethane and dried under vacuum. Loading of the
support 10 was 55 lmol/g.
4.2. Solid-phase peptide and oligonucleotide synthesis,
deprotection, and puriﬁcation of RNA-peptide conjugates
4.2.1. Solid-phase peptide synthesis on the solid supports 8, 9,
and 10
Peptides were synthesized on an Intavis MultiPep RS peptide
synthesizer with a shaking device following slightly modiﬁed stan-
dard synthesis protocols. The 3 mL reaction vessels were equipped
with a ﬁlter membrane. After each reaction step the supernatant
was extracted by suction. Initial wash: the resin (35 mg) was
washed with N,N-dimethylformamide (5  1.5 mL, 2 min each).
Fmoc deprotection: 20% (v/v) piperidine in DMF was administered
(2  450 lL, 8 and 12 min). Then, the resin was washed with N,N-
dimethylformamide (8  800 lL, 1 min each). Coupling: 2 coupling
cycles were accomplished with a reaction time of 60 min for each
step. O-(Benzotriazol-1-yl)-N,N,N0,N0-tetramethyluronium hexa-
ﬂuorophosphate (HBTU, 0.6 M in N,N-dimethylformamide,
210 lL), 4-methylmorpholine (45% in N,N-dimethylformamide,
60 lL), 1-methyl-2-pyrrolidinone (5 lL) and Fmoc-protected ami-
no acid (0.6 M in N,N-dimethylformamide, 220 lL) were mixed
(activation time: 2 min) and administered onto the resin. After cou-
pling, the resin was treated with dichloromethane (1  200 lL,
5 min). Capping: 5% (v/v) acetic anhydride, 6% (v/v) 2,6-lutidine in
N,N-dimethylformamide was administered (2  450 lL, 5 min
each). Afterwards the resin was washed with N,N-dimethylform-
amide (7  800 lL, 1 min each). Final wash: the resin was washed
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synthesized Fmoc-ON.
4.2.2. Solid-phase oligonucleotide synthesis on the peptide
charged supports 8, 9, and 10
All oligonucleotides were synthesized on a Pharmacia Gene
Assembler Plus following standard synthesis protocols. Detrityla-
tion (2.0 min): dichloroacetic acid/1,2-dichloroethane (4/96, v/v).
Coupling (3.0 min): phosphoramidites/acetonitrile (0.1 M  120
lL) were activated by 5-(benzylthio)-1H-tetrazole/acetonitrile
(0.3 M  360 lL). Capping (3  0.4 min): A: acetic anhydride/
2,4,6-trimethylpyridine/acetonitrile (2/3/5, v/v/v), B: 4-(dimethyl-
amino)pyridine/acetonitrile (0.5 M), A/B = 1/1. Oxidation (1.0
min): iodine (10 mM) in acetonitrile/2,4,6-trimethylpyridine/water
(10/1/5). Solutions of amidites, tetrazole solutions, and acetonitrile
were dried over activated molecular sieves (4Å) overnight. All se-
quences were synthesized trityl-OFF.
4.2.3. Deprotection of RNA-peptide conjugates
The beads (35 mg) were transferred into an Eppendorf tube and
equal volumes of methylamine in ethanol (8 M, 0.65 mL) and
methylamine in water (40%, 0.65 mL) were added. The mixture
was kept at room temperature for 8 h. After the supernatantwas ﬁl-
tered and evaporated to dryness, the 20-O-silyl ethers were re-
moved. RNA-peptide conjugates with a length of 4 nucleotides
were treatedwith a solution of 0.9 M tetrabutylammoniumﬂuoride
trihydrate (TBAF3H2O) in tetrahydrofuran/water (9/1, 1.0 mL) for
16 h at room temperature. Larger RNA-peptide conjugates were
treated with a solution of 1.0 M TBAF3H2O in tetrahydrofuran
(1.0 mL) for 16 h at 37 C. The reaction was quenched by the addi-
tion of triethylammonium acetate buffer (1 M, pH 7.3, 1.0 mL).
The volume of the solution was reduced to 0.5 mL and directly ap-
plied onto a puriﬁcation system (ÄKTAprime™ plus, GE Healthcare)
equipped with a size exclusion column (HiPrep™ 26/10 desalting
column, GE Healthcare). The crude conjugate was elutedwithwater,
evaporated to dryness, and dissolved in 1.0 mL water.
4.2.4. Analysis and puriﬁcation of RNA-peptide conjugates
Analysis of crude products after deprotection was performed by
anion-exchange HPLC on a Dionex DNAPac

PA-100 column
(4x250 mm) at 60 C. Flow rate: 1 mL/min; eluant A: 25 mM Tris–
HCl (pH 8.0), 6 M urea; eluant B: 25 mMTris-HCl (pH 8.0), 6 M urea,
500 mM NaClO4; gradient: 0–35% B in A within 30 min; UV-detec-
tion at 260 nm. Crude products were puriﬁed on a semi-preparative
Dionex DNAPac

PA-100 column (9x250 mm) at 60 C. Flow rate:
2 mL/min; gradient: d5–10% B in A within 20 min; UV-detection
at 260 nm. Fractions containing the oligonucleotide were loaded
on a C18 SepPak

Plus cartridge (Waters), washed with 0.15 M tri-
ethylammonium bicarbonate in water ((Et3NH)+HCO3
), water,
and eluted with water/acetonitrile (1/1, v/v)). Combined fractions
of the oligonucleotide were lyophilized to dryness and dissolved
in 1.0 mL water. The RNA yield was determined as units of optical
density at 260 nm by UV spectroscopy (Implen NanoPhotometer)
at room temperature. The product quality was veriﬁed by anion-ex-
change chromatography as described in this paragraph.
4.2.5. LC-ESI mass spectrometry of RNA-peptide conjugates
All experiments were performed on a Finnigan LCQ Advantage
MAX ion trap instrumentation (Thermo Fisher Scientiﬁc) connected
to an Amersham Ettan micro LC system (GE Healthcare). RNA-pep-
tide conjugates were analyzed in the negative-ion mode with a po-
tential of -4 kV applied to the spray needle. LC: sample: 200 pmol
lyophilized conjugate dissolved in 30 lL water for conjugates ‹ 5 nt,
200 pmol lyophilized conjugate dissolved in 30 lL 20 mM ethyl-
enediaminetetraacetic acid (EDTA) in water for conjugates › 5 nt;
column: XTerraMS, C18 2.5 lm, 1.0  50 mm at 21 C; ﬂow rate:30 lL/min; eluant A: 8.6 mM triethylamine, 100 mM 1,1,1,3,3,3-
hexaﬂuoroisopropanol in water (pH 8.0); eluant B: methanol; gra-
dient: 0–100% B in A within 20 min; UV-detection at 254 nm. Prior
each injection, column equilibration was performed by eluting buf-
fer A for 30 min at a ﬂow rate of 30 lL/min.
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